Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

But so far, most researchers are reassured as are regulators in the UK, United States and Europe.”Prof Sattar and Dr Cork have unpacked the side effects to be aware of:BlindnessStomach issues‘Ozempic ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

The findings will pave the way for semaglutide and similar drugs to become frontline treatments for this chronic condition. Losing Weight With Ozempic Might Also Lighten Your Bar Tab, Study Finds ...

Hims & Hers Health Inc (HIMS) reports a 111% revenue surge and outlines future growth strategies amid expanding service ...

25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

A confirmatory secondary endpoint at Week 72 showed 32.7% of patients treated with semaglutide ... who also have weight-related medical problems, to help them lose excess body weight and keep ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...